
AnaptysBio (ANAB) Stock Forecast & Price Target
AnaptysBio (ANAB) Analyst Ratings
Bulls say
AnaptysBio Inc. demonstrates a strong financial outlook due to the successful settlement with GSK, which significantly increased royalty rates on Jemperli sales and provided a substantial one-time payment of $60 million, enhancing the company's liquidity. The ongoing clinical development of promising antibody candidates, including rosnilimab and ANB032, positions AnaptysBio to address substantial unmet medical needs in inflammation and immuno-oncology, offering potential for substantial revenue growth. Furthermore, management's confidence in navigating the legal landscape with GSK suggests that the company maintains a viable financial buffer to support its operations and clinical programs, reinforcing a positive outlook for future performance.
Bears say
AnaptysBio Inc faces significant risks that contribute to a negative outlook on its stock, including potential safety issues with its clinical or preclinical programs and the possibility of lower-than-expected efficacy in ongoing trials. Increased commercial competition and regulatory concerns regarding the company's assets further complicate its position, threatening to hinder approval and market performance of key products such as rosnilimab and Jemperli. Additionally, unfavorable legal outcomes could adversely impact revenues and legal costs, exacerbating financial instability for the company.
This aggregate rating is based on analysts' research of AnaptysBio and is not a guaranteed prediction by Public.com or investment advice.
AnaptysBio (ANAB) Analyst Forecast & Price Prediction
Start investing in AnaptysBio (ANAB)
Order type
Buy in
Order amount
Est. shares
0 shares